Oswald Rondon, MD
Ophthalmology · Kennewick, WANPI 1285680769
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,400 of the $14,978 with a category attached, or 69.4%. AbbVie accounts for 96.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $13,814 and has fallen 98.4% since, to $228 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $226.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Sight Sciences, Inc.$158
- Alcon$110
- Glaukos Corporation$75
- Dompe US, Inc.$52
- Rayner Intraocular Lenses Limited$46
- plus $147 from 6 others
What the payments were for
- Speaking & faculty fees$10,40069%
- Travel & lodging$3,15321%
- Food & beverage$1,42510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $14,391 |
| Sight Sciences, Inc. | 3 | $158 |
| Alcon | 5 | $110 |
| Glaukos Corporation | 2 | $75 |
| Dompe US, Inc. | 2 | $52 |
| Rayner Intraocular Lenses Limited | 2 | $46 |
| Ivantis, Inc | 2 | $32 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $30 |
| NEW World Medical,inc. | 2 | $26 |
| Iridex Corporation | 1 | $25 |
| Biotissue Holdings Inc. | 1 | $18 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$13,582
- COMBIGAN$800
- OMNI(R) SURGICAL SYSTEM (US)$107
- SION SURGICAL INSTRUMENT$107
- VUITY$102
How this compares
$14,978 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 95 | $2,806 |
| Ofloxacin | 69 | $719 |
| Ketorolac Tromethamine | 39 | $582 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $547 |
| Latanoprost | 43 | $353 |
| Dorzolamide Hcl | 20 | $262 |
| Timolol Maleate | 16 | $88 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Kennewick
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- Audrey RostovBellevue$155K
- John SamplesOlympia$115K
- Barbara SmitSpokane$110K
- Debarshi MustafiSeattle$85K
- Michelle CabreraSeattle$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.